GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BrainsWay Ltd (OTCPK:BRSYF) » Definitions » EV-to-FCF

BrainsWay (BrainsWay) EV-to-FCF : -42.91 (As of May. 12, 2024)


View and export this data going back to 2012. Start your Free Trial

What is BrainsWay EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BrainsWay's Enterprise Value is $50.16 Mil. BrainsWay's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.17 Mil. Therefore, BrainsWay's EV-to-FCF for today is -42.91.

The historical rank and industry rank for BrainsWay's EV-to-FCF or its related term are showing as below:

BRSYF' s EV-to-FCF Range Over the Past 10 Years
Min: -72.83   Med: -13.7   Max: 4.23
Current: -42.88

During the past 11 years, the highest EV-to-FCF of BrainsWay was 4.23. The lowest was -72.83. And the median was -13.70.

BRSYF's EV-to-FCF is ranked worse than
100% of 363 companies
in the Medical Devices & Instruments industry
Industry Median: 27.99 vs BRSYF: -42.88

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), BrainsWay's stock price is $2.47. BrainsWay's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.130. Therefore, BrainsWay's PE Ratio for today is At Loss.


BrainsWay EV-to-FCF Historical Data

The historical data trend for BrainsWay's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BrainsWay EV-to-FCF Chart

BrainsWay Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.47 -13.23 -37.03 1.59 -51.63

BrainsWay Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.59 1.50 0.95 -4.64 -51.63

Competitive Comparison of BrainsWay's EV-to-FCF

For the Medical Devices subindustry, BrainsWay's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrainsWay's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BrainsWay's EV-to-FCF falls into.



BrainsWay EV-to-FCF Calculation

BrainsWay's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=50.164/-1.169
=-42.91

BrainsWay's current Enterprise Value is $50.16 Mil.
BrainsWay's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BrainsWay  (OTCPK:BRSYF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BrainsWay's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.47/-0.130
=At Loss

BrainsWay's share price for today is $2.47.
BrainsWay's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.130.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BrainsWay EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BrainsWay's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BrainsWay (BrainsWay) Business Description

Traded in Other Exchanges
Address
19 Hartum Street, 3rd Floor, Bynet Building, Har Hotzvim, Jerusalem, ISR, 9777518
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.